HLB saw the highest growth of 1.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.32% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of HLB’s patent filings and grants. Buy the databook here.
HLB has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 67% of filings. The World Intellectual Property Organization(WIPO), and United States(US) patent Office are among the top ten patent offices where HLB is filings its patents..
GSK and Sanofi could be the strongest competitors for HLB
In terms of grant share, HLB stands in sixth position among its competitors. GSK and Sanofi secured the top positions according to recent patent publication data.
Patents related to climate change and rare diseases lead HLB's portfolio
HLB has the highest number of patents in climate change followed by, rare diseases. For climate change, nearly 50% of patents were filed and no patents were granted in Q2 2024.
Merkel cell carcinoma related patents lead HLB portfolio
HLB has highest number of patents in merkel cell carcinoma.
For comprehensive analysis of HLB's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.